As of today more than 463 million of people have diabetes worldwide(1), and around 50 % of people having diabetes are undiagnosed.
Glycated hemoglobin (HbA1c) is a key parameter in the diagnosis of diabetes, HbA1c reflects the average blood glucose over the 3 past months.
WHO(2) has concluded, almost one decade ago, that HbA1c can be used as a diagnostic test for diabetes. An HbA1c of 6.5% (48 mmol/mol) is recommended as the cut point for diagnosing diabetes.
The HbA1c test is an indispensable part of routine management of diabetes.
Based on many years of experiences in Capillary electrophoresis technology, Sebia has adapted this technology for HbA1c testing. This innovative technology provides to laboratories and clinicians accurate and meaningful results to ensure a better patient management.